Summary
Drug-resistant epilepsy (DRE) is a form of epilepsy where seizures continue after trying at least two tolerated, appropriately chosen antiseizure medications at effective doses. About one in three people with epilepsy develop DRE. This condition can cause frequent seizures and is often associated with neuropsychiatric disorders, memory and learning problems, seizure related injuries, and a higher risk of early death. While there is no cure, a combination of medications, surgery, devices, and other therapies can help some people achieve better seizure control and improve their quality of life.
Description
Epilepsy is a long-term neurologic condition that affects the brain and causes repeated unprovoked seizures. It affects 1.0% of the population worldwide. For most people with epilepsy, seizures can be controlled with medication. However, up to 1 in 3 people continue having seizures and when this happens, the person is said to have drug-resistant epilepsy (DRE).
The International League Against Epilepsy (ILAE) defines DRE as the “failure of adequate trials of two tolerated, appropriately chosen and used antiseizure medication schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom”. This definition is important because once two medications have failed, the probability of achieving seizure freedom with more medications is low and we should think of other treatment options.
DRE affects both children and adults:
- Around 1 in 4 children with epilepsy may develop DRE.
- Around 1 in 7 adults with epilepsy may develop DRE.
DRE can have a serious impact on both the person and their family members. People with uncontrolled seizures often face mental health struggles (e.g., anxiety, depression), learning and memory difficulties, social and emotional stress. If seizures are not controlled, patients with DRE are at increased risk of premature death due to seizure related accidents, prolonged seizures (called status epilepticus), or a condition called SUDEP (Sudden Unexpected Death in Epilepsy).
Living with DRE can be difficult, but understanding the condition is the first step to finding the best care and support.
Signs and Symptoms
DRE is diagnosed when a person has persistent seizures after trying two or more appropriate medications. Seizures can present in different ways and are classified as focal, when these are arising from a specific part of the brain or generalized when these arise from the whole brain. In patients with focal epilepsy the symptoms of a seizure may vary depending on where in the brain the seizures occur and can range from subtle changes in awareness to prominent motor manifestations. Similarly, generalized epilepsies can manifest in several ways including staring, sudden jerk, or full body convulsion. Seizures can be followed by sleepiness, fatigue, confusion.
In addition to ongoing seizures, people with DRE can experience side effects of medications, learning and memory problems, behavioral or psychiatric disorders, or other symptoms that are further discussed in the related disorders section.
Causes
DRE is not caused by anything a person or family does. It can happen with any epilepsy. Most cases are not inherited, but some genetic forms of epilepsy are more likely to be drug-resistant. Sometimes, no clear cause is found. The risk for DRE is higher with:
- Specific Underlying Causes (Etiologies):
- Genetic:
- When there is a change (variant) in a gene that causes epilepsy or change in chromosomes leading to increased risk for epilepsy.
- Structural:
- A change in the brain that increases the risk for epilepsy.
- These changes can be caused by a previous infectious cause, a genetic cause, previous brain injury, or unknown reasons.
- Infectious:
- If a child had a previous infection in or around the brain that caused changes or injury to the brain.
- Inflammatory
- When a child’s immune system starts attacking its own nervous system (brain, spine, and nerves) causing seizures.
- Metabolic
- When there are difficulties in breaking down and/or storage of proteins, carbohydrates, fats, and other molecules within the body.
- Unknown
- Genetic:
- Specific Early-Onset Epilepsy Syndromes:
- Some children who develop DRE have a history of epilepsy beginning in the first several months of life. Over time, these children may continue to have seizures or develop new seizure types which are resistant to treatment. Children with these disorders also have developmental delay/disabilities.
- Epilepsy Risk Factors for DRE:
- High seizure burden
- Status epilepticus
- Multiple seizure types
- Abnormal EEG findings (epileptiform discharges)
- Abnormal imaging findings
- Focal-onset seizures
- History of febrile seizures
- Other Risk Factors for DRE:
- Seizures as a newborn
- Intellectual disability
Laboratory Investigations
To diagnose DRE and plan treatment, doctors may use:
- EEG (electroencephalogram) to record brain activity and seizure types
- MRI scans to look for brain abnormalities
- Genetic testing- genetic changes can cause epilepsy without a family history of epilepsy
- Neuropsychological testing to assess memory and learning
These tests may be repeated to monitor changes or before considering surgery.
Treatment and Therapies
There is no cure, but several options can help manage DRE:
- Medications are important even if seizures are incompletely controlled. When using anti-seizure medications, it is important to:
- Avoid using too many mediations. Using more than 3 anti-seizure medications (ASM) is unlikely to improve seizure control and can cause more side effects
- Select medications that are less likely to cause learning and behavior side effects
- Understand the interaction potential between medications
- Take all doses of medications as prescribed to reduce frequency of convulsive and prolonged seizures, which increase risk of injury and sudden unexpected death in epilepsy (SUDEP)
- Syndrome or cause-specific therapies
- Some epilepsy syndromes or causes have preferred treatments
- Metabolic disorders can present with DRE, often early in life. Many of these disorders require specific treatment, making early diagnosis important
- Autoimmune disorders may respond to immunomodulatory therapy
- Some medications have approval for specific epilepsy syndromes. These may work better than standard ASMs
- Advances are being made in understanding cause-specific epilepsy syndromes, including potential disease modifying treatments
- Epilepsy surgery involves removing or disconnecting the part of the brain that is working abnormally. This is considered if the seizures begin in an area of the brain that does not control vital functions. Those who have surgery often still need to take medication.
- Neuromodulation, or neurostimulation, devices can stimulate areas of the brain to help control seizures and reduce seizure frequency. They are typically used with medications. Some neuromodulation devices require surgery to implant a device. The neuromodulation device that is approved for children is the vagus nerve stimulator.
- Ketogenic diets: A special high-fat, low-carbohydrate diet may improve seizure control in children and adults. It can be used for all types of epilepsy. The diet is very strict and can be challenging to follow but can also be very effective in providing seizure control, especially in children.
- Seizure rescue plan: All people with epilepsy should have a seizure action plan so that families, schools, and communities know how to respond when the person has a seizure. If there is risk for prolonged or very frequent seizures, rescue medication is often prescribed. Families and caregivers should understand how and when to give the rescue medication.
- Comprehensive care: Physical, occupational, and psychological therapies support learning, mood, and daily living and are essential for all children and families living with epilepsy.
Outlook
Many children with DRE continue to have seizures into adulthood, but some can have major improvement or rarely achieve seizure freedom from seizures with surgery or devices. DRE can affect independence, school, work, and social life. DRE is associated with an increased risk of developmental delays, intellectual disability, and learning disorders, Children may need special education services and modified learning plans. There is an increased risk of problems with attention (such as in attention deficit hyperactivity disorder), memory, and behavior. There is also an increased risk of mood disorders, such as anxiety and depression. Most people need ongoing support and may not be able to drive or live independently. In people with DRE, the rates of unemployment are higher compared to the general population, and it may be hard for a person with DRE to find and maintain a job. The risk of injury, often seizure-related, and early death is higher, especially from SUDEP.
It is important for children with DRE to receive specialized care and evaluation at a Comprehensive Epilepsy Center. This evaluation should occur early and once a diagnosis of DRE has been made to make sure that other treatments, such as a ketogenic diet, epilepsy surgery, or specialty medications, have been considered. In some cases, starting a specific therapy or undergoing early surgical intervention can dramatically improve seizure frequency and improve other factors such as development, cognitive abilities, and overall quality of life, as well as reduce the risk of seizure-related injury and SUDEP.
Resources
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
We are dedicated to improving the lives of individuals impacted by LGS through advancing research, awareness, education, and family support.
Research
ClinicalTrials.gov for DRE (birth to 17 years)
These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
For more information about participation in clinical trials, check out our education hub on the topic here.
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
Fauser S, Tumani H. Epilepsy. Handb Clin Neurol. 2017;146:259-266. doi: 10.1016/B978-0-12-804279-3.00015-0. PMID: 29110774.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922. PMID: 19889013.
Sultana B, Panzini MA, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, Bauer PR, Kwon CS, Jetté N, Josephson CB, Keezer MR. Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis. Neurology. 2021 Apr 27;96(17):805-817. doi: 10.1212/WNL.0000000000011839. Epub 2021 Mar 15. PMID: 33722992.
Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014 Aug;37:59-70. doi: 10.1016/j.yebeh.2014.05.031. Epub 2014 Jun 27. PMID: 24980390.
Beniczky S, Trinka E, Wirrell E, Abdulla F, Al Baradie R, Alonso Vanegas M, Auvin S, Singh MB, Blumenfeld H, Bogacz Fressola A, Caraballo R, Carreno M, Cendes F, Charway A, Cook M, Craiu D, Ezeala-Adikaibe B, Frauscher B, French J, Gule MV, Higurashi N, Ikeda A, Jansen FE, Jobst B, Kahane P, Kishk N, Khoo CS, Vinayan KP, Lagae L, Lim KS, Lizcano A, McGonigal A, Perez-Gosiengfiao KT, Ryvlin P, Specchio N, Sperling MR, Stefan H, Tatum W, Tripathi M, Yacubian EM, Wiebe S, Wilmshurst J, Zhou D, Cross JH. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025 Jun;66(6):1804-1823. doi: 10.1111/epi.18338. Epub 2025 Apr 23. PMID: 40264351; PMCID: PMC12169392.
Auvin S, Specchio N. Pharmacotherapeutic strategies for drug-resistant epilepsy in children. Epilepsy Behav. 2024 Dec;161:110139. doi: 10.1016/j.yebeh.2024.110139. Epub 2024 Nov 7. PMID: 39515006.
Perplexity AI, Inc. Perplexity [Internet]. San Francisco (CA): Perplexity AI, Inc.; 2025 [cited 2025 Oct 24]. Available from: https://www.perplexity.ai
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory